Clinical Trials Logo
  1. Home
  2. Low Grade Glioma
  3. NCT03363217

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Low-grade Glioma Clinical Trial

Official title:
A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Clinical Trial Summary

This is a phase 2, open-label, interventional clinical trial that will study the response rate of pediatric glioma and plexiform neurofibroma (PN) to oral administration of trametinib. Patients meeting all inclusion criteria for a given study group will receive the study medication at a daily dose of 0.025 mg/kg up to a total of 18 cycles, in 28-day cycles. A total of 150 patients will be recruited as part of this clinical study. Patients aged between 1 month (corrected age) and 25 years old will be eligible, in order to include a maximum of patients affected by low-grade glioma (LGG) and PN. This study includes four groups: patients with neurofibromatosis type 1 (NF1) and LGG, NF1 patients with PN, patients with LGG with a B-Raf Serine/Threonine-protein Kinase/Proto-oncogene Encoding B-Raf (BRAF) fusion and patients with glioma of any grade with activation of the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinases (MAPK/ERK) pathway. All patients except patients with PN must have failed at least one line of treatment. The study will also explore the molecular mechanisms behind tumor development, progression and resistance to treatment. Furthermore, this study will also explore important aspects for patients with brain tumors by including assessment of quality of life and neuropsychological evaluation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03363217
Study type Interventional
Source St. Justine's Hospital
Contact
Status Active, not recruiting
Phase Phase 2
Start date August 16, 2018
Completion date March 1, 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04734444 - SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue N/A
Recruiting NCT01837862 - A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Phase 1/Phase 2
Recruiting NCT06104488 - A Study of Avutometinib for People With Solid Tumor Cancers Phase 1
Completed NCT04659421 - Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas Phase 2
Recruiting NCT04174820 - Child's Study of the Impact of PF Lesion on Motor Skills, Language, Cognitive Functioning and Social Cognition
Completed NCT02197637 - Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma Phase 2
Completed NCT05373394 - Evaluation of Cognitive and Motor Neurological Disorders in the Short and Long Term After Surgery for the Removal of a Diffuse Low-grade Glioma of the Supplementary Motor Area
Recruiting NCT05406700 - Niraparib In Recurrent IDH 1/2 Gliomas Early Phase 1
Active, not recruiting NCT04865315 - A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors
Recruiting NCT06159478 - Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) Phase 2
Recruiting NCT06381570 - Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas Early Phase 1
Terminated NCT03763422 - Trial in Low Grade Glioma Patients: Wait or Treat Phase 3
Completed NCT04346472 - Longitudinal MRI Assessment in Patients With Diffuse Low-grade Gliomas
Active, not recruiting NCT03948490 - Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas N/A
Recruiting NCT04923126 - SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma Phase 1/Phase 2
Completed NCT00782626 - Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas Phase 2
Completed NCT05873946 - Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery
Not yet recruiting NCT05555550 - Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG Early Phase 1
Withdrawn NCT05233215 - GROW (Glioma Specialists Reaching Out With Support) Support N/A
Completed NCT01497860 - Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas Phase 2